The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Eli Lilly chairman and Chief Executive Officer David ... Health News // 2 days ago FDA issues norovirus warning on frozen oysters from South Korea May 23 (UPI) -- The U.S. Food and Drug ...

Wednesday saw drugmaker Eli Lilly pledge $27 billion toward creating ... I feel deeply, deeply connected to the U.S.” South Korean automaker Hyundai is also considering moving some of its ...